NASDAQ:PODD - Insulet Stock Price, Forecast & News

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet Co. (NASDAQ:PODD) issued its quarterly earnings results on Tuesday, November, 5th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.03 by $0.02. The medical instruments supplier earned $192.12 million during the quarter, compared to analysts' expectations of $179.50 million. Insulet had a return on equity of 10.34% and a net margin of 2.38%. Insulet's quarterly revenue was up 27.2% compared to the same quarter last year. During the same period last year, the firm posted $0.03 earnings per share. View Insulet's Earnings History.

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Insulet.

Insulet will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

17 Wall Street analysts have issued 1-year target prices for Insulet's stock. Their forecasts range from $100.00 to $213.00. On average, they anticipate Insulet's share price to reach $162.06 in the next twelve months. This suggests that the stock has a possible downside of 23.7%. View Analyst Price Targets for Insulet.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insulet.

News articles about PODD stock have been trending very positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Insulet earned a coverage optimism score of 3.1 on InfoTrie's scale. They also assigned media stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), DexCom (DXCM), Tandem Diabetes Care (TNDM), Roku (ROKU), Splunk (SPLK), salesforce.com (CRM), Veeva Systems (VEEV) and Adobe (ADBE).

Insulet's stock is owned by a number of of institutional and retail investors. Top institutional investors include Capital Research Global Investors (10.81%), Capital World Investors (6.47%), William Blair Investment Management LLC (2.59%), Fred Alger Management LLC (2.34%), Alliancebernstein L.P. (1.43%) and Geode Capital Management LLC (1.15%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including CSS LLC IL, Capital Research Global Investors, Fred Alger Management LLC, Goldman Sachs Group Inc., Alliancebernstein L.P., Jennison Associates LLC, Eagle Asset Management Inc. and Russell Investments Group Ltd.. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

PODD stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, Renaissance Technologies LLC, Beacon Investment Advisory Services Inc., Sumitomo Mitsui Trust Holdings Inc., Capital International Investors, UBS Asset Management Americas Inc., Swiss National Bank and SG Americas Securities LLC. View Insider Buying and Selling for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $212.31.

Insulet has a market capitalization of $13.13 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

The official website for Insulet is http://www.insulet.com/.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]m.